Drug Development Department, Gustave Roussy Comprehensive Cancer Center, Villejuif, France.
Clin Cancer Res. 2016 Dec 15;22(24):5956-5958. doi: 10.1158/1078-0432.CCR-16-2033. Epub 2016 Sep 28.
Anti-PD1 antibodies have led to a therapeutic shift in cancer treatment. Although classically described as "well tolerated," these drugs can lead to severe immune-related adverse events. Using CT scan imaging, Nishino and colleagues describe different radiologic patterns and their possible relation to severity of several cases of anti-PD1-induced pneumonitis. Clin Cancer Res; 22(24); 5956-8. ©2016 AACRSee related article by Nishino et al., p. 6051.
抗 PD1 抗体在癌症治疗中引发了治疗模式的转变。尽管这些药物通常被描述为“具有良好的耐受性”,但它们也可能导致严重的免疫相关不良反应。Nishino 及其同事使用 CT 扫描成像描述了不同的影像学模式,以及它们与几种抗 PD1 诱导性肺炎严重程度的可能关系。临床癌症研究;22(24);5956-8. ©2016AACR 参见 Nishino 等人的相关文章,第 6051 页。